Admissions:
None
Delistings:
Samarkand Group (SMK.PM) has withdrawn from the Aquis Stock Exchange
None
1Spatial 44.5p £56.76m (SPA.L)
The global Location Master Data Management software and solutions Company announces finals to January 2025. There is a 3% increase in revenue to £33.4m of which 62% is recurring up from 56%, last year. The operating profit decreased to £0.9m from £1.4m reflecting higher costs with a net debt of £1m compared to net cash of £1.1m. The Company continues to leverage its established customer base and partners with 22 US states, following two additions. Enhancing product offerings is ongoing as expansion opportunities are developed with existing customers. Further investment is being made in high margin solutions targeting utilities and local government in the UK and US. The slower pace of decision making, most notably in the US, is likely to continue impacting growth.
Accsys Technologies 48.5p £116.6m (AXS.L)
The supplier of premium, high performance and sustainable wood building materials updates on trading for FY March 2025 reporting a strong performance expecting to deliver results in line with the previously upgraded market consensus of an adjusted EBITDA of EU10.5m, which would be on an 8% increase in revenue to EU147.4m. This is evidence of the progress in delivering on Phase 1 of its FOCUS strategy to Transform and Improve. The net debt at end March 2025 is EU42.6m representing an increase of EU2.4m which was driven by planned US investment and higher inventory levels. Currently, tariff exemptions are in place for lumber imports into the US and the Company's US manufacturing plant enables Accsys to serve US customers with locally manufactured product. Funding is in place to support growth prospects.
Aptamer Group 0.365p £7.27m (APTA.L)
The developer of next-generation synthetic binders yesterday reported the successful adaptation of the Optimer-based test for Alzheimer's disease into a format widely accepted and used in hospital laboratories. The test being developed leverages non-invasive saliva sampling offering a rapid, convenient and patient-friendly approach. The Alzheimer's disease diagnostic market is valued at $8.3bn, limited by the availability of any definitive diagnostic tests, and is expected to rise to $19.6bn by 2029. Aptamer has also finalised a 15-year royalty agreement with its development partner, Neuro-Bio Ltd. Under the agreed terms, Aptamer is eligible to receive royalty payments with a blended royalty rate of 11.1% on the first £166m of sales, with 5% thereafter.
B90 Holdings 2.35p £10.35m (B90.L)
The online marketing Company for the gaming industry specialising in customer acquisition reports finals to December 2024. Revenue increased 4% to EURO3.52m with a positive EBITDA of EURO0.7m compared to an EBITDA loss of EURO3.3m.The is drive by a significant reduction in total administrative expenses reflecting the benefits of the move to a B2B-focused operational model. The cash reserves stood at EURO0.36m at the year end. The Company secured over 200 B2B partnerships with industry players and further organic growth is expected with a focus on innovative marketing strategies, to grow the base of partnerships, including some major brands.
Cooks Coffee Company Limited 8.50p £5.45m (AQSE: Cook)
The international coffee focused café chain has entered into a Master Franchise Agreement for India. The agreement is with a Special Purpose Vehicle, Sterling Coffee House, which has local expertise and a proven track record. Under the terms, the Franchisee will be responsible for the establishment and operation of the business in India, with ongoing support from Cooks Coffee. This support will include providing systems, processes, and best practices related to the Esquires brand. The Indian coffee retail chain market was valued at $18.83bn for the year to March 2025 and is projected to grow at a CAGR of 9.84% to 2030.
CT Automotive Group 23.5p £17.3m (CTA.L)
The designer, developer, and supplier of interior components to the global automotive industry reports finals to December 2024. Revenue decreased 16% $119.7m with an adjusted PBT 5% higher at $8.7m reflecting a 6% increase in gross profit margin to 28%. Net debt however increased to $6.2m from $3.8m. The Company’s response to the headwinds facing the auto industry was to focus on streamlining operations driven by the successful adoption of key digitisation and automation strategies. The CEO expects the current unsettled environment will create some opportunities to help customers find efficiencies and long-term solutions for their future production plans.
Fusion Antibodies 6.0p £6.29m (FAB.L)
The specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, updated on trading yesterday. Its revenues increased 71.9% to £1.96m because of significant growth in the Diagnostics sector with increasing interest from early-stage smaller-scale prospects in the Veterinary sector. The downturn in venture capital investment into biotechnology companies, which is affecting Fusion’s clients, appears be slowly easing. The approval of the Future Medicines Institute £1m grant is non-dilutive cash income and the initial payment was not included in the March cash position of £0.4m, nor was £0.57m from the £1.17m placing on 18 March 2025. The non-discounted placing was backed by VCTs supporting the commercialisation strategy, as well as R&D. The OptiMAL platform is gaining traction with larger pharmaceutical and biotech clients and further resources are to be committed to its development.
Hercules Site Services 48.5p £38.62m (HERC.L)
The technology-enabled labour supply Company for the UK infrastructure and construction sectors provides a trading update to March 2025, and the interim results are to be published in mid-June. Revenue is expected to be more than 17% higher at £54m which is in line with market expectations. This revenue growth has been underpinned by continuing momentum at key infrastructure sites in the UK, and boosted by government commitment to the sector. The Company saw a significant increase in tender enquiries during Q2 and into Q3 across the water, highways, rail, power, oil & gas, and energy sectors, reflecting the growing confidence in UK infrastructure investment.
Shearwater Group 32p £5.51m (SWG.L)
The cybersecurity, advisory, and managed security services Group announces a major data security contract, worth £4.4m over three years. The new contract is with a prominent UK-based mass media and telecommunications provider. The Group will provide strategic solutions delivering a robust data-centric security and compliance platform. The solution equips security and compliance teams with advanced capabilities, including integrated data visibility, predictive analytics, and automation, enabling proactive protection of sensitive data regardless of where it resides. The revenue and cost of sales will be recognised in FY25, supporting expected results that which will show significant growth in both revenue and Adjusted EBITDA from FY24.
Various Eateries 13.5p £23.63m (VARE.L)
The UK developer and operator of restaurant, clubhouse and hotel sites updates on trading for the 26-week (Interim) period to March 2025. Sales of £24.7m show an 8.8% increase driven primarily by the contribution of new site opening as like-for-like sales were flat year-on-year. There is a strong performance from proven, all-season venues such as Coppa Club Tower Bridge and Tavolino. The operational performance continued to improve, with site-level EBITDA increasing by 81% and profitability is ahead of last year. Cash at bank at the end of March 2025 was £6.0m compared to £7.2m. The approach to expansion will continue be disciplined and measured.
Status of this Note and Disclaimer
This document has been provided as a general market commentary and is issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as investment advice; a recommendation; an offer to sell; nor solicitation of any offer to buy any security or other financial instrument. Nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. The information has been provided without taking into account the investment objective, financial situation or needs of any particular person. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
As market commentary, this document is not investment research or a research recommendation for regulatory purposes as it does not constitute substantive research or analysis. It is not subject to any prohibition on dealing ahead of the dissemination of investment research although Hybridan LLP maintains related internal systems and controls in connection with such dealing.
This document should not be relied upon as being an independent or impartial view of the subject matter. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result, both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
This document is not intended to be an invitation or inducement to engage in investment activity. In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are categorised by Hybridan LLP as either a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority's Conduct of Business Sourcebook) (all such persons referred to in (i) and (ii) together being referred to as "relevant persons"). This document must not be acted on or relied up on by persons who are not relevant persons. For the avoidance of doubt, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority's Conduct of Business Sourcebook.
The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. The information may contain projections or other forward-looking statements regarding future events, targets or expectations. There is no assurance that such events or expectations will be achieved, and actual results may be significantly different from that shown here. The information is based on current market conditions, which will fluctuate and may be superseded by subsequent market events or for other reasons. Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein.
References to specific securities, asset classes and financial markets are for illustrative purposes only. Past performance is no guarantee of future results. Information and opinions presented have been obtained or derived from sources which Hybridan LLP reasonably believed to be reliable however no representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.
To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any losses arising in any way from use of all or any part of the information in this document including, for the avoidance of doubt, direct or indirect or consequential loss or damage (including lost profits).
Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom or any other jurisdiction in any part of the world.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication.
In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
Unless otherwise stated, Hybridan LLP owns the intellectual property rights and any other rights in this document. This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.
